FOXO TECHNOLOGIES INC.'S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS
Robert Merritt, Chief of Executive Officer of Myrtle stated, 'We appreciate the support from Scott County to provide care for uninsured patients from the community that might otherwise not receive the care they need. To receive this support for a second year running combined with our facility operating at capacity and with a waiting list of patients is an acclamation for the quality of care our clinical team provides. We look forward to further expanding our footprint and offering our proven clinical program to an expanded patient base'
Seamus Lagan, Chief Executive Officer of parent company, FOXO Technologies Inc., further added, 'We are pleased at how Myrtle has ramped up operations and made a significant impact in the rural communities it serves. We look forward to expanding Myrtle into additional locations through organic growth and acquisition and believe this subsidiary will contribute significant revenue and value to FOXO in future years. Furthermore as we exit the first half of the year we are excited for the second half of 2025 and look forward to demonstrating continued successes achieved in the second quarter, in our upcoming quarterly report to June 30th, when filed'
About FOXO Technologies Inc. ('FOXO')
FOXO owns and operates three subsidiaries.
Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.
Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.
FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.
For more information about FOXO, visit www.foxotechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business; the ability to implement FOXO's business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO's intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO's most recent reports on Forms 10-K and 10-Q, particularly the 'Risk Factors' sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Sebastien Sainsbury
[email protected]
(561) 485-0151
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate
Kentucky Gov. Andy Beshear speaks during the Semafor World Economy Summit 2025 at Conrad Washington on April 23, 2025 in Washington, DC. () LINCOLN — Kentucky Gov. Andy Beshear is coming to Nebraska to speak to Democrats for the state party's top annual fundraising event in November. Beshear is a Democratic governor in a deeply red Republican state. He and other 2028 potential presidential hopefuls visited South Carolina in recent weeks, to test the water for their campaign messages. He was picked to lead the Democratic Governors Association into next year's midterm elections and has been touted as 'most popular Democratic governor in America.' Beshear was attorney general of Kentucky before becoming governor in 2019. His father was previously governor. National Democrats have been seeking answers as President Donald Trump made gains among working-class voters, including minority voters, last year. A trend of prominent Democratic figures making their way to the heartland has emerged, and some are crossing the Missouri River from traditionally first-in-the-nation Iowa into Nebraska. Independent U.S. Sen. Bernie Sanders launched his 'Fighting Oligarchy' nationwide tour in Omaha. Minnesota Gov. Tim Walz hosted a Democratic town hall earlier this year And Former Texas U.S. Rep. Beto O'Rourke is having a similar town hall in Omaha next month. The events with prominent Democratic figures appear aimed at energizing the Nebraska Democratic base for the midterms and come when two federal races could be competitive. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Nebraska's 2nd Congressional District has drawn national attention as its single presidential race electoral vote has swung from Republicans to Democrats in recent years, most recently to former Vice President Kamala Harris in 2024. Nebraska could regain the national spotlight in 2026, with an open seat race in the state's 2nd District for the U.S. House and Dan Osborn's nonpartisan Senate bid against Republican U.S. Sen. Pete Ricketts. Both races could determine which party controls what parts of Congress. But Nebraska Democrats face an uphill battle in a state where Republicans outnumber Democrats about 2 to 1, Republicans have gained a legislative supermajority, and the party last held a congressional seat with former U.S. Rep. Brad Ashford in 2017. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
9 minutes ago
- Yahoo
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the 'Existing Warrants') to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements which were filed and declared effective by the Securities and Exchange Commission (the 'SEC'). The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $3.9 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the 'Replacement Warrants') to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act'). The Replacement Warrants will be exercisable, beginning on the effective date of stockholder approval, into an aggregate of up to 8,637,810 shares of common stock, at an exercise price of $0.9047 per share, and a term of exercise equal to five years from the date of shareholder approval. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The Replacement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Replacement Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Forward Looking Statements This communication contains 'forward-looking' statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected closing of the offering. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company's Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas 908-824-0775PALI@
Yahoo
9 minutes ago
- Yahoo
Tesla disappoints on earnings but wins on one major front
Tesla disappoints on earnings but wins on one major front originally appeared on TheStreet. Tesla didn't mention Bitcoin once in its second-quarter 2025 financial filing, even as investors and analysts scanned the company's balance sheet for any sign of movement in its crypto treasury. The silence isn't new. Tesla hasn't added or sold any Bitcoin for eight straight quarters, and the company's digital asset holdings remain unchanged at $184 million, according to the 10-Q form filed with the SEC on July 23. That's the same value it reported in the first quarter of 2024, with no impairment losses or gains noted this time either. Tesla had initially bought $1.5 billion worth of Bitcoin in early 2021. Since then, it's sold off the majority, with the last major sale happening in Q2 2022 when it offloaded roughly 75% of its BTC stash. Tesla holds 9,720 BTC as of its last disclosure. At today's Bitcoin price of $118,000, that stash is worth approximately $1.15 declines Beyond crypto, Tesla's earnings disappointed on several fronts. The company reported revenue of $22.5 billion — missing analyst estimates of $22.74 billion — and adjusted earnings per share of $0.40, below the expected $0.43. Automotive revenue fell 16% year-over-year, the second straight quarterly decline. In early July, Tesla had already reported a 14% drop in Q2 vehicle deliveries to 384,000 units. The stock is down roughly 18% this year, marking the worst performance among big tech names. By comparison, the Nasdaq Composite is up about 9% in 2025. Meanwhile, Tesla has delayed its affordable 'Model 2' EV, leaving the field open for rivals. Chinese EV makers are aggressively pushing cheaper, tech-laden vehicles that are eating into Tesla's global market share. Still holding the bag Despite the financial and political turbulence, Tesla appears to be holding firm on its crypto position—for now. But with mounting pressure from declining revenues and reputational hits, investors are watching closely for any future changes to the company's digital asset strategy. As of now, though, the Bitcoin line in Tesla's earnings reports remains quiet. No buys. No sells. Just HODLing. Tesla disappoints on earnings but wins on one major front first appeared on TheStreet on Jul 23, 2025 This story was originally reported by TheStreet on Jul 23, 2025, where it first appeared. Sign in to access your portfolio
